USE OF PASTEURIZED AKKERMANSIA FOR TREATING METABOLIC DISORDERS
The present invention relates to pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder in a subject in need thereof. The present invention also relates to a composition, a pharmaceutical composition and a medicament comprising pasteurized Akkermansia muciniphila or fragments thereof for treating a metabolic disorder. The present invention also relates to the use of pasteurized Akkermansia muciniphila or fragments thereof for promoting weight loss in a subject in need thereof.
1 . A method for treating a metabolic disorder in a subject in need thereof, comprising administering to the subject Akkermansia muciniphila or fragments thereof, wherein the Akkermansia muciniphila is pasteurized.
2 . The method of claim 1 , wherein said metabolic disorder is obesity.
3 . The method of claim 1 , wherein said metabolic disorder is selected from the group consisting of: metabolic syndrome; insulin-deficiency or insulin-resistance related disorders; diabetes mellitus including type 2 diabetes; glucose intolerance; abnormal lipid metabolism; atherosclerosis; hypertension; pre-eclampsia; cardiac pathology; stroke; non-alcoholic fatty liver disease; hyperglycemia; hepatic steatosis; liver diseases including fibrosis associated with obesity and abnormal liver functions, more particularly changes in bile production and immunity; dyslipidemia; dysfunction of the immune system associated with overweight and obesity; inflammatory, immune and barrier function diseases including inflammatory bowel disease, more particularly Crohn's disease and ulcerative colitis, and irritable bowel syndrome; cardiovascular diseases; high cholesterol; elevated triglycerides; asthma; sleep apnea; osteoarthritis; neuro-degeneration; gallbladder disease; syndrome X; atherogenic dyslipidemia; and cancer.
4 . A method for
a) increasing energy expenditure of a subject, optionally without impacting the food intake of said subject; or
b) increasing satiety in a subject,
comprising administering Akkermansia muciniphila or fragments thereof to the subject, wherein the Akkermansia muciniphila is pasteurized.
5 . (canceled)
6 . The method of claim 1 , wherein the Akkermansia muciniphila is orally administered.
7 . The method of claim 1 , wherein the Akkermansia muciniphila is administered to the subject in an amount from about 1.10 4 to about 1.10 12 cells, about 1.10 5 to about 1.10 11 cells, or from about 1.10 6 to about 1.10 10 cells.
8 . The method of claim 1 , wherein the Akkermansia muciniphila is administered at least three times a week.
9 . The method of claim 1 , wherein the Akkermansia muciniphila is co-administered with another probiotic strain and/or another bacteria and/or microorganisms with beneficial effects and/or with one or more prebiotics.
10 . The method of claim 1 , wherein the Akkermansia muciniphila or fragments thereof is administered as a composition according to any one of claims 1 to 9 in association with an excipient.
11 . The method of claim 10 , wherein said composition is a nutritional composition.
12 . The method of claim 10 , wherein said composition is orally administered.
13 . The method of claim 1 , wherein the Akkermansia muciniphila is administered as a pharmaceutical composition in association with a pharmaceutically acceptable vehicle.
14 . (canceled)
15 . A method for weight loss in a subject in need thereof, comprising administering Akkermansia muciniphila or fragments thereof to the subject, wherein the Akkermansia muciniphila is pasteurized.
16 . The method of claim 15 , wherein the Akkermansia muciniphila is administered as a cosmetic composition, and wherein the Akkermansia muciniphila is pasteurized.